Comparison of scoring methods for ACE-27: Simpler is better

Journal of Geriatric Oncology

Volumn 3, Issue 3, 2012, Pages 238-245

  Kallogjeri, Dorina ^a   Piccirillo, Jay F ^a   Spitznagel, Edward L ^b   Steyerberg, Ewout W ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer patients; Comorbidity comorbid ailment; Elderly; Prognostic; Survival

Indexed keywords

ADULT COMORBIDITY EVALUATION 27 INDEX; AFRICAN AMERICAN; AGED; AKAIKE INFORMATION CRITERION; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GERIATRIC PATIENT; HARRELL C INDEX; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; KAPLAN FEINSTEIN INDEX; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL RATE;

EID: 84862498887     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2012.01.006     Document Type: Article

References (32)

1. Piccirillo J.F., Feinstein A.R. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996 Mar 1, 77(5):834-842.
2. Read W.L., Tierney R.M., Page N.C., Costas I., Govindan R., Spitznagel E.L., et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004 Aug 1, 22(15):3099-3103.
3. Surveillance Epidemiology and End Results (SEER) program. SEER Stat Fact Sheets 2009.
4. Satariano W.A. Comorbidities and cancer. Cancer in the elderly 2000, 477-499. Marcel Dekker, New York. 1st ed. C.P. Hunter, K.A. Johnson, H.B. Muss (Eds.).
5. Albertsen P.C., Fryback D.G., Storer B.E., Kolon T.F., Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996 Jul, 156(1):127-132.
6. Yancik R., Wesley M.N., Ries L.G., Havlik R.J., Long S., Edwards B.K., et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients-a population-based study. Cancer 1998 Jun 1, 82(11):2123-2134.
7. Smith A.W., Reeve B.B., Bellizzi K.M., Harlan L.C., Klabunde C.N., Amsellem M., et al. Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev 2008, 29(4):41-56.
8. Bellizzi K.M., Mustian K.M., Palesh O.G., Diefenbach M. Cancer survivorship and aging: moving the science forward. Cancer 2008 Dec 15, 113(12 Suppl.):3530-3539.
9. Piccirillo J.F., Vlahiotis A., Barrett L.B., Flood K.L., Spitznagel E.L., Steyerberg E.W. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008 Aug, 67(2):124-132.
10. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
11. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000 Sep, 35(3):181-200.
12. Colinet B., Bertrand D., Lacombe S., Bozonnat M.C., Daures J.P., Pujol J.L., et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005 Nov 14, 93(10):1098-1105.
13. Kaplan M.H., Feinstein A.R. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974, 27(7-8):387-404.
14. Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004 May 26, 291(20):2441-2447.
15. Johnston A.S., Piccirillo J.F., Creech C.M., Littenberg B., Jeffe D., Spitznagel E.L.J. Validation of a comorbidity education program. J Registry Manag 2001, 28(3):125-131.
16. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974, 19(6):716-723.
17. Steyerberg E.W. Clinical prediction models: a practical approach to development, validation, and updating 2009, Statistics for Biology and Health, Springer New York.
18. Harrell F.E., Lee K.L., Mark D.B. Tutorials in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med Feb 28 1996, 15(4):361-387.
19. Piccirillo J.F., Creech C.M., Zequeira R., Anderson S., Johnston A.S. Inclusion of comorbidity into oncology data registries. J Registry Manag 1999, 26(2):66-70.
20. Coebergh JW., Post P.N., Razenberg P.P. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 1999 Dec, 52(12):1131-1136.
21. Sundarajan V., Quan H., Halfon P., Fushimi K., Luthi J.C., Burnand B., et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care 2007, 45(12):1210-1215.
22. Cleves M.A., Sanchez N., Draheim M. Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data. J Clin Epidemiol 1997, 50(8):903-908.
23. Ghali W.A., Hall R.E., Rosen A.K., Ash A.S., Moskowitz M.A. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1996, 49(3):273-278.
24. D'Hoore W., Bouckaert A., Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996, 49(12):1429-1433.
25. Fang A., Piccirillo J.F. A comparison of the claims-based ICD-9-CM and the chart-based approaches to classifying comorbidity and complications by hospital-based cancer registrars. J Registry Manag 2006, 33(1):10-16.
26. Wells C.K., Stoller J.K., Feinstein A.R., Horwitz R.I. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med 1984, 144(10):2004-2009.
27. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120(2):104-110.
28. Stukenborg G.J., Wagner D.P., Connors A.F.J. Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations. Med Care 2001 Jul, 39(7):727-739.
29. Elixhauser A., Steiner C., Harris R., Coffey R.M. Comorbidity measures for use with administrative data. Med Care 1998, 36(1):8-27.
30. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
31. Wang C.Y., Baldwin L.M., Saver B.G., Dobie S.A., Green P.K., Cai Y., et al. The contribution of longitudinal comorbidity measurements to survival analysis. Med Care 2009, 47(7):813-820.
32. Yung K.C., Piccirillo J.F. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg 2008 Oct, 134(10):1045-1049.